Rhenman & Partners Asset Management AB lessened its position in shares of Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) by 53.3% in the 4th quarter, HoldingsChannel reports. The institutional investor owned 100,400 shares of the company’s stock after selling 114,600 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Apellis Pharmaceuticals were […]
Crestline Management LP decreased its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX – Free Report) by 25.1% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 100,649 shares of the company’s stock after selling 33,815 shares during the quarter. Crestline Management LP owned […]
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) Director Amy W. Schulman sold 21,700 shares of Alnylam Pharmaceuticals stock in a transaction on Wednesday, May 29th. The stock was sold at an average price of $148.60, for a total value of $3,224,620.00. Following the transaction, the director now directly owns 8,436 shares of the company’s […]
StockNews.com upgraded shares of Agios Pharmaceuticals (NASDAQ:AGIO – Free Report) from a sell rating to a hold rating in a research note issued to investors on Wednesday. Several other analysts also recently weighed in on AGIO. Royal Bank of Canada reduced their target price on Agios Pharmaceuticals from $43.00 to $42.00 and set an outperform […]
Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) has been given an average rating of “Buy” by the four ratings firms that are currently covering the stock, MarketBeat Ratings reports. Four investment analysts have rated the stock with a buy recommendation. The average 1 year target price among brokerages that have issued a report on […]